News & Views | Published:

Tuberculosis vaccines—a new kid on the block

Nature Medicine volume 17, pages 159160 (2011) | Download Citation

New tuberculosis vaccines are urgently needed to reduce the threat of this devastating disease. An approach consisting of a fusion protein of three tuberculosis antigens provides significant protection in before- and after-exposure challenge mouse models, representing a crucial step forward in tackling tuberculosis in latently infected individuals (pages 189–194).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Lancet 375, 2110–2119 (2010).

  2. 2.

    et al. Nat. Med. 17, 189–194 (2011).

  3. 3.

    , , , & PLoS ONE 4, e6950 (2009).

  4. 4.

    , , , & Mol. Microbiol. 43, 717–731 (2002).

  5. 5.

    , & Immunol. Rev. 211, 58–66 (2006).

  6. 6.

    & Nat. Immunol. 6, 1063–1066 (2005).

  7. 7.

    et al. Lancet 366, 1290–1295 (2005).

  8. 8.

    et al. Am. J. Respir. Crit. Care Med. 179, 724–733 (2009).

  9. 9.

    World Health Organization. Wkly. Epidemiol. Rec. 82, 193–196 (2007).

  10. 10.

    Immunity 33, 567–577 (2010).

  11. 11.

    World Health Organization. (Geneva, WHO Press, 2006).

Download references

Author information

Affiliations

  1. Stefan H. E. Kaufmann is at the Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany.

    • Stefan H E Kaufmann

Authors

  1. Search for Stefan H E Kaufmann in:

Competing interests

S.H.E.K. is co-inventor of a tuberculosis vaccine candidate currently in clinical trial.

Corresponding author

Correspondence to Stefan H E Kaufmann.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0211-159

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing